Skip to main content
SpringerLink
Log in

Male Hypogonadism

An Update on Diagnosis and Treatment

  • Review Article
  • Published:
Treatments in Endocrinology

Abstract

Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Hypogonadism associated with aging (andropause) may present a mixed picture, with low testosterone levels and low to low-normal gonado-tropin levels. Androgen replacement therapy in hypogonadal men has many potential benefits: improved sexual function, an enhanced sense of well-being, increased lean body mass, decreased body fat, and increased bone density. However, it also carries potential risks, including the possibility of stimulating the growth of an occult prostate cancer. The benefits of androgen therapy outweigh the risks in men with classic hypogonadism. However, for men with mild hypogonadism or andropause, the balance between benefits and risks is not always clear. Unfortunately, studies to date have included too small a number of patients and have been too short in duration to provide meaningful data on the long-term risks versus the benefits of androgen replacement therapy in these populations. Several products are currently marketed for the treatment of male hypogonadism. Weekly-to-biweekly injections of testosterone cypionate (cipionate) or testosterone enanthate (enantate) are widely used, as they are economical and generally well tolerated. However, once-daily transdermal therapies have become increasingly popular and now include both patch and gel systems. Intramuscular injection of testosterone undecanoate is an attractive new therapy that can be administered quarterly. To confirm an adequate replacement dosage, assessment of clinical responses and measurement of serum testosterone levels generally suffice. For selected men, serial measurement of bone mineral density during androgen therapy might be helpful to confirm end-organ effects. For men aged >50 years, we advocate measurement of hematocrit for detection of polycythemia and a digital rectal examination with a serum prostate-specific antigen level measurement for prostate cancer screening during the first few months of androgen therapy. Subsequently, a hematocrit should be obtained yearly or after changes in therapy, and annual prostate cancer screening can be offered to the patient after a discussion of its risks and benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Smyth CM, Bremner WJ. Klinefelter syndrome. Arch Intern Med 1998; 158(12): 1309–14

    Article  PubMed  CAS  Google Scholar 

  2. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86(2): 724–31

    Article  PubMed  CAS  Google Scholar 

  3. Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89(12): 5920–6

    Article  PubMed  CAS  Google Scholar 

  4. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49(9): 1239–42

    Article  PubMed  CAS  Google Scholar 

  5. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000; 53(6): 703–11

    Article  CAS  Google Scholar 

  6. Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89(2): 534–43

    Article  PubMed  CAS  Google Scholar 

  7. Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002; 5(3): 170–6

    PubMed  CAS  Google Scholar 

  8. Morley JE, Patrick P, Perry III HM. Evaluation of assays available to measure free testosterone. Metabolism 2002; 51(5): 554–9

    Article  PubMed  CAS  Google Scholar 

  9. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84(10): 3666–72

    Article  PubMed  CAS  Google Scholar 

  10. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem 1998; 44(10): 2178–82

    PubMed  CAS  Google Scholar 

  11. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56(6): 1278–81

    Article  PubMed  CAS  Google Scholar 

  12. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989; 10(5): 366–71

    PubMed  CAS  Google Scholar 

  13. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58(6): 710–7

    Article  CAS  Google Scholar 

  14. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85(12): 4500–10

    Article  PubMed  CAS  Google Scholar 

  15. Christ-Crain M, Mueller B, Gasser TC, et al. Is there a clinical relevance of partial androgen deficiency of the aging male? J Urol 2004; 172(2): 624–7

    Article  PubMed  CAS  Google Scholar 

  16. Vermeulen A. Andropause. Maturitas 2000; 34(1): 5–15

    Article  PubMed  CAS  Google Scholar 

  17. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001; 110(7): 563–72

    Article  PubMed  CAS  Google Scholar 

  18. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57(2): M76–99

    Article  PubMed  Google Scholar 

  19. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003; 51(1): 101–15

    Article  PubMed  Google Scholar 

  20. Morley JE, Perry III HM. Andropause: an old concept in new clothing. Clin Geriatr Med 2003; 19(3): 507–28

    Article  PubMed  Google Scholar 

  21. Lunenfeld B. Androgen therapy in the aging male. World J Urol 2003; 21(5): 292–305

    Article  PubMed  CAS  Google Scholar 

  22. Alexandersen P, Christiansen C. The aging male: testosterone deficiency and testosterone replacement: an update. Atherosclerosis 2004; 173(2): 157–69

    Article  PubMed  CAS  Google Scholar 

  23. Carey PO, Howards SS, Vance ML. Transdermal testosterone treatment of hypogonadal men. J Urol 1988; 140(1): 76–9

    PubMed  CAS  Google Scholar 

  24. Conway AJ, Boylan LM, Howe C, et al. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 1988; 11(4): 247–64

    Article  PubMed  CAS  Google Scholar 

  25. Burris AS, Ewing LL, Sherins RJ. Initial trial of slow-release testosterone micro-spheres in hypogonadal men. Fertil Steril 1988; 50(3): 493–7

    PubMed  CAS  Google Scholar 

  26. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15(3): 212–5

    PubMed  CAS  Google Scholar 

  27. Salehian B, Wang C, Alexander G, et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate. A clinical research center study. J Clin Endocrinol Metab 1995; 80(12): 3567–75

    Article  PubMed  CAS  Google Scholar 

  28. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81(10): 3654–62

    Article  PubMed  CAS  Google Scholar 

  29. Dobs AS, Hoover DR, Chen MC, et al. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 1998; 83(1): 33–9

    Article  PubMed  CAS  Google Scholar 

  30. Nieschlag E, Buchter D, Von Eckardstein S, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999; 51(6): 757–63

    Article  CAS  Google Scholar 

  31. Zhang GY, Gu YQ, Wang XH, et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 1998; 19(6): 761–8

    PubMed  CAS  Google Scholar 

  32. Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 155(5): 1604–8

    Article  PubMed  CAS  Google Scholar 

  33. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997; 47(6): 727–37

    Article  CAS  Google Scholar 

  34. Morales A, Johnston B, Heaton JP, et al. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997; 157(3): 849–54

    Article  PubMed  CAS  Google Scholar 

  35. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82(11): 3793–6

    Article  PubMed  CAS  Google Scholar 

  36. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84(10): 3469–78

    Article  PubMed  CAS  Google Scholar 

  37. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men: Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85(8): 2839–53

    Article  PubMed  CAS  Google Scholar 

  38. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002; 23(3): 419–25

    Google Scholar 

  39. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91(1): 69–74

    Article  PubMed  CAS  Google Scholar 

  40. Park NC, Yan BQ, Chung JM, et al. Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 2003; 6(2): 86–93

    PubMed  CAS  Google Scholar 

  41. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88(6): 2673–81

    Article  PubMed  CAS  Google Scholar 

  42. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel®) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89(5): 2085–98

    Article  PubMed  CAS  Google Scholar 

  43. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281(6): El 172–81

    Google Scholar 

  44. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90(7): 3838–46

    Article  PubMed  CAS  Google Scholar 

  45. Chemana D, Morville R, Fiet J, et al. Percutaneous absorption of 5 alpha-dihydrotestosterone in man: II. Percutaneous administration of 5 alpha-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. Int J Androl 1982; 5(6): 595–606

    Article  PubMed  CAS  Google Scholar 

  46. Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002; 87(4): 1467–72

    Article  PubMed  CAS  Google Scholar 

  47. Anderson RA, Martin CW, Kung AW, et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999; 84(10): 3556–62

    Article  PubMed  CAS  Google Scholar 

  48. Anderson RA, Wallace AM, Sattar N, et al. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 2003; 88(6): 2784–93

    Article  PubMed  CAS  Google Scholar 

  49. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75(4): 1092–8

    Article  PubMed  CAS  Google Scholar 

  50. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81(10): 3469–75

    Article  PubMed  CAS  Google Scholar 

  51. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81(12): 4358–65

    Article  PubMed  CAS  Google Scholar 

  52. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82(2): 407–13

    Article  PubMed  CAS  Google Scholar 

  53. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(8): 2647–53

    Article  PubMed  CAS  Google Scholar 

  54. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85(8): 2670–7

    Article  PubMed  CAS  Google Scholar 

  55. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282(3): E601–7

    PubMed  CAS  Google Scholar 

  56. Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002; 87(12): 5649–57

    Article  PubMed  CAS  Google Scholar 

  57. Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58(7): 618–25

    Article  PubMed  Google Scholar 

  58. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90(3): 1502–10

    Article  PubMed  CAS  Google Scholar 

  59. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82(6): 1661–7

    Article  PubMed  CAS  Google Scholar 

  60. Ly LP, Jimenez M, Zhuang TN, et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001; 86(9): 4078–88

    Article  PubMed  CAS  Google Scholar 

  61. Morley JE, Perry III HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41(2): 149–52

    PubMed  CAS  Google Scholar 

  62. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269 (5 Pt 1): E820–6

    PubMed  CAS  Google Scholar 

  63. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl 1999; 22(4): 261–5

    Article  PubMed  CAS  Google Scholar 

  64. Szulc P, Claustrat B, Marchand F, et al. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003; 88(11): 5240–7

    Article  PubMed  CAS  Google Scholar 

  65. Greenspan SL, Neer RM, Ridgway EC, et al. Osteoporosis in men with hyperpro-lactinemic hypogonadism. Ann Intern Med 1986; 104(6): 777–82

    PubMed  CAS  Google Scholar 

  66. Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991; 6(1): 39–43

    Article  PubMed  CAS  Google Scholar 

  67. Arisaka O, Arisaka M, Nakayama Y, et al. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. Metabolism 1995; 44(4): 419–23

    Article  PubMed  CAS  Google Scholar 

  68. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106(3): 354–61

    PubMed  CAS  Google Scholar 

  69. Choi HR, Lim SK, Lee MS. Site-specific effect of testosterone on bone mineral density in male hypogonadism. J Korean Med Sci 1995; 10(6): 431–5

    PubMed  CAS  Google Scholar 

  70. Kenny AM, Prestwood KM, Marcello KM, et al. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 2000; 55(9): M492–7

    Article  PubMed  CAS  Google Scholar 

  71. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992; 304(1): 4–8

    Article  PubMed  CAS  Google Scholar 

  72. Devogelaer JP, De Cooman S, Nagant de Deuxchaisnes C. Low bone mass in hypogonadal males: effect of testosterone substitution therapy, a densitometric study. Maturitas 1992; 15(1): 17–23

    Article  PubMed  CAS  Google Scholar 

  73. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82(8): 2386–90

    Article  PubMed  CAS  Google Scholar 

  74. Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69(4): 776–83

    Article  PubMed  CAS  Google Scholar 

  75. Leifke E, Korner HC, Link TM, et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998; 138(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  76. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(6): 1966–72

    Article  PubMed  CAS  Google Scholar 

  77. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001; 54(6): 739–50

    Article  Google Scholar 

  78. Schubert M, Bullmann C, Minnemann T, et al. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003; 60(1): 21–8

    Article  PubMed  CAS  Google Scholar 

  79. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89(2): 503–10

    Article  PubMed  CAS  Google Scholar 

  80. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56(5): M266–72

    Article  PubMed  CAS  Google Scholar 

  81. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331(16): 1056–61

    Article  PubMed  CAS  Google Scholar 

  82. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80(12): 3689–98

    Article  PubMed  CAS  Google Scholar 

  83. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339(9): 599–603

    Article  PubMed  CAS  Google Scholar 

  84. Matsumoto AM, Tenover L, McClung M, et al. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002; 167(5): 2105–8

    Article  PubMed  Google Scholar 

  85. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81(10): 3578–83

    Article  PubMed  CAS  Google Scholar 

  86. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74(3): 623–8

    Article  PubMed  CAS  Google Scholar 

  87. Kenny AM, Fabregas G, Song C, et al. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004; 59(1): 75–8

    Article  PubMed  Google Scholar 

  88. Pope Jr HG, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(1): 105–11

    Article  PubMed  Google Scholar 

  89. Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am 2002; 29(4): 975–82

    Article  PubMed  Google Scholar 

  90. Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24(3): 299–311

    PubMed  Google Scholar 

  91. Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male 2003; 6(3): 166–74

    PubMed  CAS  Google Scholar 

  92. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350(5): 482–92

    Article  PubMed  CAS  Google Scholar 

  93. Schultheiss D, Machtens S, Jonas U. Testosterone therapy in the ageing male: what about the prostate? Andrologia 2004; 36(6): 355–65

    Article  PubMed  CAS  Google Scholar 

  94. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18(4): 847–53

    PubMed  CAS  Google Scholar 

  95. Eaton NE, Reeves GK, Appleby PN, et al. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999; 80(7): 930–4

    Article  PubMed  CAS  Google Scholar 

  96. Morgentaler A, Bruning III CO, De Wolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276(23): 1904–6

    Article  PubMed  CAS  Google Scholar 

  97. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1410–6

    PubMed  CAS  Google Scholar 

  98. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004; 108(3): 418–24

    Article  PubMed  CAS  Google Scholar 

  99. Svetec DA, Canby ED, Thompson IM, et al. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997; 158(5): 1775–7

    Article  PubMed  CAS  Google Scholar 

  100. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 2003; 58(11): 1002–8

    Article  PubMed  Google Scholar 

  101. Overman CT, Blazer DG. Committee on assessing the need for clinical trials of testosterone replacement therapy. Washington (DC): National Academies Press, 2004

    Google Scholar 

  102. de Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med 1993; 25(3): 235–41

    Article  PubMed  Google Scholar 

  103. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349(3): 215–24

    Article  PubMed  CAS  Google Scholar 

  104. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24(2): 183–217

    Article  PubMed  CAS  Google Scholar 

  105. Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111(4): 261–9

    Article  PubMed  CAS  Google Scholar 

  106. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102(16): 1906–11

    Article  PubMed  CAS  Google Scholar 

  107. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90(8): 871–6

    Article  PubMed  CAS  Google Scholar 

  108. Bagatell CJ, Bremner WJ. Androgens in me: uses and abuses. N Engl J Med 1996; 334(11): 707–14

    Article  PubMed  CAS  Google Scholar 

  109. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003; 21(5): 311–5

    Article  PubMed  CAS  Google Scholar 

  110. Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, Striant®, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004; 89(5): 2039–43

    Article  PubMed  CAS  Google Scholar 

  111. Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant®) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89(8): 3821–9

    Article  PubMed  CAS  Google Scholar 

  112. Jockenhovel F, Bullmann C, Schubert M, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999; 48(5): 590–6

    Article  PubMed  CAS  Google Scholar 

  113. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004; 64(17): 1861–91

    Article  PubMed  CAS  Google Scholar 

  114. Stuenkel CA, Dudley RE, Yen SS. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab 1991; 72(5): 1054–9

    Article  PubMed  CAS  Google Scholar 

  115. Amory JK, Scriba GK, Amory DW, et al. Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. J Androl 2003; 24(5): 716–20

    PubMed  CAS  Google Scholar 

  116. Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 2005; 90(5): 2610–7

    Article  PubMed  CAS  Google Scholar 

  117. Schulte-Beerbuhl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil Steril 1980; 33(2): 201–3

    PubMed  CAS  Google Scholar 

  118. Grant NN, Anawalt BD. Male hypogonadism in the primary care clinic. Prim Care Clin Office Pract 2003; 30(4): 743–63

    Article  Google Scholar 

  119. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51(6): 1335–9

    Article  PubMed  CAS  Google Scholar 

  120. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 1987; 47(6): 1004–9

    PubMed  CAS  Google Scholar 

  121. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 1995; 10(4): 862–5

    PubMed  CAS  Google Scholar 

  122. Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999; 140(5): 414–9

    Article  PubMed  CAS  Google Scholar 

  123. Testosterone undecanoate: Schering AG. Drugs RD 2004; 5 (6): 368–9

  124. Rajalakshmi M, Ramakrishnan PR. Pharmacokinetics and pharmacodynamics of a new long-acting androgen ester: maintenance of physiological androgen levels for 4 months after a single injection. Contraception 1989; 40(4): 399–412

    Article  PubMed  CAS  Google Scholar 

  125. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992; 75(5): 1204–10

    Article  PubMed  CAS  Google Scholar 

  126. Tschop M, Behre HM, Nieschlag E, et al. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate. Clin Chem Lab Med 1998; 36(4): 223–30

    Article  PubMed  CAS  Google Scholar 

  127. Bhasin S, Swerdloff RS, Steiner B, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74(1): 75–83

    Article  PubMed  CAS  Google Scholar 

  128. Amory JK, Anawalt BD, Blaskovich PD, et al. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel®) in hypogonadal men. J Androl 2002; 23(1): 84–91

    PubMed  CAS  Google Scholar 

  129. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 2001; 55(4): 531–6

    Article  CAS  Google Scholar 

  130. Jockenhovel F, Vogel E, Kreutzer M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996; 45(1): 61–71

    Article  CAS  Google Scholar 

  131. Handelsman DJ, Mackey MA, Howe C, et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 1997; 47(3): 311–6

    Article  CAS  Google Scholar 

  132. Kelleher S, Turner L, Howe C, et al. Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol (Oxf) 1999; 51(4): 469–71

    Article  CAS  Google Scholar 

  133. Kelleher S, Conway AJ, Handelsman DJ. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 2002; 146(4): 513–8

    Article  PubMed  CAS  Google Scholar 

  134. Kelleher S, Howe C, Conway AJ, et al. Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol (Oxf) 2004; 60(4): 420–8

    Article  CAS  Google Scholar 

  135. Zacharin MR, Warne GL. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child 1997; 76(6): 495–9

    Article  PubMed  CAS  Google Scholar 

  136. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989; 68(2): 369–73

    Article  PubMed  CAS  Google Scholar 

  137. Ahmed SR, Boucher AE, Manni A, et al. Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988; 66(3): 546–51

    Article  PubMed  CAS  Google Scholar 

  138. Bals-Pratsch M, Langer K, Place VA, et al. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 1988; 118(1): 7–13

    CAS  Google Scholar 

  139. Behre HM, von Eckardstein S, Kliesch S, et al. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol (Oxf) 1999; 50(5): 629–35

    Article  CAS  Google Scholar 

  140. Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site. A clinical research center study. J Clin Endocrinol Metab 1996; 81(5): 1832–40

    Article  PubMed  CAS  Google Scholar 

  141. Yu Z, Gupta SK, Hwang SS, et al. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol 1997; 37(12): 1139–45

    PubMed  CAS  Google Scholar 

  142. Yu Z, Gupta SK, Hwang SS, et al. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. J Clin Pharmacol 1997; 37(12): 1129–38

    PubMed  CAS  Google Scholar 

  143. Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86(6): 2437–45

    Article  PubMed  CAS  Google Scholar 

  144. JordanJr WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 1998; 20(1): 80–7

    Article  PubMed  CAS  Google Scholar 

  145. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf) 1999; 50(1): 57–62

    Article  CAS  Google Scholar 

  146. Wilson DE, Kaidbey K, Boike SC, et al. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20(2): 299–306

    Article  PubMed  Google Scholar 

  147. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites. A General Clinical Research Center Study. J Clin Endocrinol Metab 2000; 85(3): 964–9

    Article  PubMed  CAS  Google Scholar 

  148. Dobs AS, Matsumoto AM, Wang C, et al. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 2004; 20(5): 729–38

    Article  PubMed  CAS  Google Scholar 

  149. Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim®, compared to AndroGel®. Biopharm Drug Dispos 2003; 24(3): 115–20

    Article  PubMed  CAS  Google Scholar 

  150. Meikle AW, Matthias D, Hoffman AR. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU Int 2004; 93(6): 789–95

    Article  PubMed  CAS  Google Scholar 

  151. Rolf C, Knie U, Lemmnitz G, et al. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 2002; 56(5): 637–41

    Article  CAS  Google Scholar 

  152. Fiet J, Morville R, Chemama D, et al. Percutaneous absorption of 5 alpha-dihydrotestosterone in man: I. Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5 alpha-dihydrotestosterone. Int J Androl 1982; 5(6): 586–94

    Article  PubMed  CAS  Google Scholar 

  153. Wang C, Iranmanesh A, Berman N, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men: a clinical research center study. J Clin Endocrinol Metab 1998; 83(8): 2749–57

    Article  PubMed  CAS  Google Scholar 

  154. Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002; 87(4): 1462–6

    Article  PubMed  CAS  Google Scholar 

  155. Kumar N, Didolkar AK, Monder C, et al. The biological activity of 7alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130(6): 3677–83

    Article  PubMed  CAS  Google Scholar 

  156. Cummings DE, Kumar N, Bardin CW, et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998; 83(12): 4212–9

    Article  PubMed  CAS  Google Scholar 

  157. Suvisaari J, Moo-Young A, Juhakoski A, et al. Pharmacokinetics of 7alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. Contraception 1999; 60(5): 299–303

    Article  PubMed  CAS  Google Scholar 

  158. Noe G, Suvisaari J, Martin C, et al. Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum Reprod 1999; 14(9): 2200–6

    Article  PubMed  CAS  Google Scholar 

  159. Yin D, Gao W, Kearbey JD, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003; 304(3): 1334–40

    Article  PubMed  CAS  Google Scholar 

  160. Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004; 145(12): 5420–8

    Article  PubMed  CAS  Google Scholar 

  161. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 2000; 161(1–2): 73–88

    Article  PubMed  CAS  Google Scholar 

  162. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocr Pract 2002; 8(6): 440–56

    Google Scholar 

  163. Proceedings of the Endocrine Society Andropause Consensus Conferences. In: Swerdloff RS, editor. Andropause Consensus Panel. Boston (MA): The Endocrine Society, 2000

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors would like to thank Anne Lee, PharmD, and Alice Moy for their assistance in the preparation of table V. The authors are also grateful to Dr John Amory and Dr Alvin Matsumoto for their critical review of the manuscript.

Author information

Authors and Affiliations

  1. Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, S-CHF-1, 1660 South Columbia Way, Seattle, Washington, 98108, USA

    Emily Darby &  Bradley D. Anawalt

Authors
  1. Emily Darby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradley D. Anawalt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradley D. Anawalt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Darby, E., Anawalt, B.D. Male Hypogonadism. Mol Diag Ther 4, 293–309 (2005). https://doi.org/10.2165/00024677-200504050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200504050-00003

Keywords

Search

Navigation